Erythropoietin-Stimulating Agent Hyporesponsiveness in Patients Living with Chronic Kidney Disease
Kidney Diseases · 2022 · 8 (2) · 103-114
DOI: 10.1159/000521162 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Kidney Diseases, online erschienen am 14.01.2022. Verfasst von Henry H L Wu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal Medicine, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, United Kingdom. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background: Erythropoietin-stimulating agent (ESA) hyporesponsiveness is commonly observed in patients with anemia secondary to chronic kidney disease (CKD). Because of its complexity, a global consensus on how we should define ESA hyporesponsiveness remains unavailable. The reported prevalence and demographic information on ESA hyporesponsiveness within the CKD population are variable with no consensus definition. Summary: ESA hyporesponsiveness is defined as having no increase in hemoglobin concentration from baseline after the first month of treatment on appropriate weight-based dosing. The important factors associated with ESA hyporesponsiveness include absolute or functional iron deficiency, inflammation, and uremia. Hepcidin has been demonstrated to play an important role in this process. Mineral bone disease secondary to CKD and non-iron malnutrition among other factors are also associated with ESA hyporesponsiveness. There is continued debate toward determining a gold-standard treatment pathway to manage ESA hyporesponsiveness. The development of hypoxia-inducing factor-stabilizers brings new insights and opportunities in the management of ESA hyporesponsiveness. Key Message: Management of ESA hyporesponsiveness involves a comprehensive multidisciplinary team approach to address its risk factors. The progression of basic and clinical research on identifying risk factors and management of ESA hyporesponsiveness brings greater hope on finding solutions to eventually tackling one of the most difficult problems in the topic of anemia in CKD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Renal Medicine, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, United Kingdom.
- Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
- Department of Renal Medicine, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom.
Zitieren
APA
Wu, H. H. L., & Chinnadurai, R. (2022). Erythropoietin-Stimulating Agent Hyporesponsiveness in Patients Living with Chronic Kidney Disease. Kidney Diseases, 8(2), 103-114. https://doi.org/10.1159/000521162
Vancouver
Wu HHL, Chinnadurai R. Erythropoietin-Stimulating Agent Hyporesponsiveness in Patients Living with Chronic Kidney Disease. Kidney Diseases. 2022;8(2):103-114. doi:10.1159/000521162
BibTeX
@article{Wu2022,
author = {Wu, Henry H L and Chinnadurai, Rajkumar},
title = {Erythropoietin-Stimulating Agent Hyporesponsiveness in Patients Living with Chronic Kidney Disease},
journal = {Kidney Diseases},
year = {2022},
volume = {8},
number = {2},
pages = {103--114},
doi = {10.1159/000521162}
}
EUVIMED